Edgewise Therapeutics, Inc. (NASDAQ: EWTX), a burgeoning player in the biotechnology sector, is attracting significant interest from investors, largely due to its promising pipeline of therapies aimed at tackling muscle disorders. With a market capitalization of $3.19 billion, the company is making notable strides in the healthcare industry with its innovative approach to treating dystrophinopathies, including Duchenne and Becker muscular dystrophies.

Currently priced at $30.09, Edgewise Therapeutics’ stock has shown resilience and growth, flirting with its 52-week high of $31.00. This strong performance is underscored by a remarkable potential upside of 26.84%, based on the average target price of $38.17 set by analysts who are…